External low-dose dexamethasone at the initial stage of treatment has been reported to be helpful in improving the efficacy of anti-PD-1 treatment in cancer by suppressing immune evasion (11, 12), so we address the question of whether intermediate levels of endogenous GC are therapeutically more beneficial than both higher and lower levels of GC. The gene discussed is PDCD1; the disease is cancer.